Lisanti Capital Growth LLC Purchases New Holdings in NeoGenomics, Inc. $NEO

Lisanti Capital Growth LLC bought a new position in shares of NeoGenomics, Inc. (NASDAQ:NEO) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 74,200 shares of the medical research company’s stock, valued at approximately $1,362,000. Lisanti Capital Growth LLC owned approximately 0.06% of NeoGenomics as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in the company. Jacobi Capital Management LLC bought a new position in shares of NeoGenomics in the 3rd quarter valued at $37,000. Illinois Municipal Retirement Fund increased its position in NeoGenomics by 6.1% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 67,830 shares of the medical research company’s stock valued at $1,245,000 after acquiring an additional 3,915 shares during the period. Fulcrum Asset Management LLP raised its position in NeoGenomics by 2,554.7% during the 3rd quarter. Fulcrum Asset Management LLP now owns 3,398 shares of the medical research company’s stock worth $64,000 after purchasing an additional 3,270 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of NeoGenomics in the third quarter worth approximately $29,000. Finally, GAMMA Investing LLC lifted its position in shares of NeoGenomics by 30.1% in the 3rd quarter. GAMMA Investing LLC now owns 2,782 shares of the medical research company’s stock worth $51,000 after purchasing an additional 644 shares during the period. 98.50% of the stock is owned by institutional investors.

NeoGenomics Trading Down 0.8%

Shares of NEO opened at $16.83 on Thursday. The stock’s 50-day simple moving average is $17.59 and its 200 day simple moving average is $12.98. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.53 and a quick ratio of 3.31. NeoGenomics, Inc. has a 52-week low of $7.07 and a 52-week high of $20.15.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $209.25 million for the quarter, compared to analyst estimates of $206.70 million. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. NeoGenomics’s revenue was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.03 EPS. Research analysts forecast that NeoGenomics, Inc. will post -0.06 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on NEO. Needham & Company LLC raised their target price on NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 price objective on shares of NeoGenomics in a report on Thursday, October 29th. Wall Street Zen upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Sunday. Benchmark lifted their price target on NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Finally, BTIG Research reissued a “buy” rating and set a $28.00 target price on shares of NeoGenomics in a research report on Thursday, October 29th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

About NeoGenomics

NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.